Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib - PubMed
3 hours ago
- #Real-World Study
- #JAK Inhibitor
- #Atopic Dermatitis
- Abrocitinib, a JAK-1 inhibitor, is effective for moderate-to-severe atopic dermatitis (AD).
- A 16-week study in South Korea showed significant improvement in EASI scores with abrocitinib.
- 94.4%, 72.2%, and 25.9% of patients achieved EASI-50, -75, and -90 respectively by week 16.
- Abrocitinib was effective even in patients who previously failed biologics or other JAK inhibitors.
- The most common side effects were acne (43.9%), urticaria (24.6%), and herpes simplex infection (12.3%).
- No patients discontinued treatment due to adverse events.
- Abrocitinib showed numerically higher response rates compared to upadacitinib and baricitinib.
- The study supports abrocitinib as a well-tolerated and effective treatment for AD in real-world settings.